Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 066
FDA modifies the list of recognized standards under the Food and Drug Administration Modernization Act of 1997, impacting compliance requirements for pharmaceutical manufacturers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 22, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B). should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate review recommended; no specific deadline stated.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Modifications to the recognized standards list may affect compliance with current good manufacturing practices (cGMP) and other regulatory requirements.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B).
What you must do
Review the updated list of recognized standards and adjust manufacturing practices accordingly to ensure compliance.
Deadline
Immediate review recommended; no specific deadline stated.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- DEA Urges Judge to Move Marijuana to Schedule III as Final Rescheduling Briefs Set Stage for Decision - The Marijuana Herald
- 5,000 ppm fluoride toothpaste needs expert guidance, FDA says - Nation Thailand
- FDA issues draft guidance on assessing container and closure systems for drugs and biologics - RAPS
- FDA’s New Rules Aim to Make Pharma Ads Easier to Understand - Pain News Network
- Evaluation of Therapeutic Equivalence; Guidance for Industry; Availability